Received Feb 6, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | Y014510 | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | Y015599 | — |
No additional AE; the patient uhm who was above the age of 45 was given 2 doses of GARDASIL 9 and came in to receive their 3rd dos; the patient uhm who was above the age of 45 was given 2 doses of GARDASIL 9 and came in to receive their 3rd dos; This spontaneous report was received from a pharmacist via agency and refers to a 73-year-old male patient. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 17-Jul-2025, the patient started vaccination with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL9) suspension for injection (lot #Y014510, expiration date: 01-Nov-2026), dose number 1, administered as prophylaxis (Product administered to patient of inappropriate age). On 18-Sep-2025, the patient was vaccinated with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL9) suspension for injection (lot #Y015599, expiration date: 10-Feb-2027), dose number 2, administered as prophylaxis (Product administered to patient of inappropriate age). No additional adverse events. At the reporting time, the outcome of the events was unknown. The action taken with Human Papillomavirus 9-valent Vaccine, Recombinant and Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL9) was not applicable. This is one of the two reports from the same reporter.